Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Medical technology momentum setup: Q2 revenue grew 48% YoY to $64.1M, gross margin improved to 83%, and full-year 2026 revenue guidance was raised to $246M-$250M; the stock surged about 70% over 21 trading days and remains near recent highs.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Negative Cash Flow HTFL offers strong liquidity and low leverage, but persistent losses, cash burn, and premium valuation warrant caution despite improving margins.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly rally ⢠$50 resistance ⢠Volatile pullback Support Level: $45.49â$46.67 Resistance Level: $50.00â$50.43 HTFL remains bullish over the last month above $45.49â$46.67 support, but a decisive break above $50.43 is needed to resume the advance.
Sentiment & News
Key News Insights: ⢠Raised guidance ⢠Clinical validation ⢠Competitive concerns HeartFlow's strong earnings, raised guidance, and supportive clinical data boost its outlook, though competitive pressure and insider sales remain key risks.
AI Summary
HTFL's upside now hinges on Plaque Analysis scaling from $1.5M to roughly $30M in 2026 and proving Heartflow can convert its broader coronary-AI platform into reimbursed, high-margin recurring revenue; investors should watch adoption, reimbursement, and narrowing cash losses closely, as its ~12.7x sales valuation leaves little tolerance for a slower ramp.
Description
HeartFlow offers a non-invasive diagnostic platform that converts a single coronary CT angiogram into a patient-specific 3D heart model and applies computational fluid dynamics and related analytics to quantify blood flow, arterial narrowing, and plaque characteristics. Founded in 2007 and based in Mountain View, California, the company distributes its technology globally to support clinical assessment and management of coronary artery disease.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 17 | Aug 24 | HTFL | Heartflow, Inc. Common Stock | Medical technology momentum setup: Q2 revenue grew 48% YoY to $64.1M, gross margin improved to 83%, and full-year 2026 revenue guidance was raised to $246M-$250M; the stock surged about 70% over 21 trading days and remains near recent highs. | Closed | +19.7% |
| Mar 23 | Mar 30 | HTFL | Heartflow, Inc. Common Stock | HeartFlow (HTFL) has multiple fresh growth catalystsâAetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000âpatient NAVIGATEâPCI registry on March 16, 2026âand its stock has surged ~20â30% off the March low, positioning it as a highâbeta, event-driven healthcare IT momentum trade despite ongoing operating losses. | Closed | -11.0% |